Despite further promising results indicating a correlation of good ORR with expression of PD-L1 in lung cancer (PD1 expression ≥1% ORR 57% vs. 28%) [11, 21], the predictive value of PD-1/PD-L1 expression for nivolumab-based therapies is not fully understood in most tumor entities. This evidence concerns the gene PDCD1 and lung carcinoma.